Tesamorelin

Tesamorelin research material, available in 5 mg, 10 mg, 20 mg vials. For in-vitro research only.

• Adding a trans-3-hexenoyl moiety to Tyr1 of the 1-44 amide made the analogue resistant to dipeptidyl aminopeptidase IV and slowed its in-vitro degradation in rat, dog and human plasma. [1]
• Enzyme kinetics on the parent hormone placed the dipeptidyl peptidase IV cleavage between Ala2 and Asp3, the bond the N-terminal modification is built to protect. [2]
• A validated immunopurification and high resolution mass spectrometry method reached a limit of detection of 0.2 ng/mL and a limit of identification of 0.5 ng/mL for the analogue and related growth hormone releasing hormone peptides. [3]
• In-vitro metabolism work on four larger growth hormone releasing hormone analogues identified nineteen major metabolites, which were then synthesized as reference materials for a liquid chromatography tandem mass spectrometry method. [4]

Compound

Tesamorelin

Purity

99.50% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

5 mg · 10 mg · 20 mg

Catalog / lot

RV-0046 / RV-24-0046-1

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.